ADMA Biologics, Inc. ("ADMA" or the Company) is a commercial biopharmaceutical company committed to manufacturing, marketing and developing specialty plasma-derived products for the prevention and treatment of infectious diseases in the immune compromised and other patients at risk for infection.

According to the Complaint, On January 21, 2017, the Board caused the Company to enter into an agreement and plan of purchase ("Purchase Agreement"), pursuant to which the Company will acquire certain assets and assume certain liabilities constituting the therapy business of Biotest (the "Proposed Transaction") in exchange for an aggregate equity interest in ADMA equal to approximately 50% of the issued and outstanding ADMA capital stock (the "Purchase Consideration").

The Complaint alleges on April 26, 2017, in order to convince ADMA shareholders to vote in favor of the Proposed Transaction, the Board authorized the filing of a materially incomplete and misleading Definitive Proxy Statement with the Securities and Exchange Commission, in violation of Sections 14(a) and 20(a) of the Exchange Act.

On May 10, 2017, Plaintiff filed a Notice voluntarily dismissing this action. The Court granted an Order of Dismissal on May 16.